Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Operating Leases: 2019-2024

Historic Operating Leases for Madrigal Pharmaceuticals (MDGL) over the last 5 years, with Dec 2024 value amounting to $1.0 million.

  • Madrigal Pharmaceuticals' Operating Leases rose 373.30% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 373.30%. This contributed to the annual value of $1.0 million for FY2024, which is 14.17% down from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Operating Leases stood at $1.0 million for FY2024, which was down 14.17% from $1.2 million recorded in FY2023.
  • Over the past 5 years, Madrigal Pharmaceuticals' Operating Leases peaked at $1.2 million during FY2023, and registered a low of $387,000 during FY2021.
  • Over the past 2 years, Madrigal Pharmaceuticals' median Operating Leases value was $1.1 million (recorded in 2023), while the average stood at $1.1 million.
  • Per our database at Business Quant, Madrigal Pharmaceuticals' Operating Leases climbed by 29.64% in 2020 and then decreased by 17.31% in 2021.
  • Over the past 4 years, Madrigal Pharmaceuticals' Operating Leases (Yearly) stood at $468,000 in 2020, then fell by 17.31% to $387,000 in 2021, then reached $1.2 million in 2023, then declined by 14.17% to $1.0 million in 2024.